# Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

> **NCT02360657** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 18 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** JNJ-54861911, 10 mg
- **DRUG:** JNJ-54861911, 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02360657
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-16
- **Primary completion:** 2015-09-08
- **Final completion:** 2015-09-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360657, "Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02360657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*